Anaplastic Astrocytoma Market - Forecast(2023 - 2028)
Anaplastic Astrocytoma Market Overview
Anaplastic Astrocytoma Market size is estimated to reach $7.8 billion by 2027, growing at a CAGR of 4.3% during the forecast period 2022-2027. “Anaplastic astrocytoma” identified as malignant gliomas and can be delineated as sporadic malignant brain tumors arising from astrocytes which are star-shaped cells in the brain. A prominent factor in the prevalence of this cancer is associated with heredity. People afflicted with an inherited condition such as Li Fraumeni syndrome, hereditary nonpolyposis colorectal cancer, or Lynch syndrome are more likely to develop astrocytoma. Besides, rare skin, eyes, and heart ailments such as tuberous sclerosis instigated by mutations in genes TSC1 and TSC2 have their fair contribution to the existence of anaplastic astrocytoma. This disease can induce many medical complications including vision problems, drowsiness, nausea, and weakness. The anaplastic astrocytoma market outlook appears positive with an unusual spread. With enlarging stress and depression, poor diet intake, augmenting nuclear plants setup are factors set to drive the growth of the Anaplastic Astrocytoma Market for the period 2022-2027.
The report: “Anaplastic Astrocytoma Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Anaplastic Astrocytoma Market.
Treatment Type: Surgery, Chemotherapy, and Radiation.
By Disease Grades: Low grade (Grade1, Grade2) and High grade (Grade3, Grade4).
By Treatment Product: Kinase Inhibitors and Alkylating agents.
By Treatment Phase: Pre-registration and Clinical trial Phase.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of World (the Middle East and Africa).
- Geographically, the North America Anaplastic Astrocytoma Market accounted for the highest revenue share in 2021. Nevertheless, Asia-Pacific is poised to dominate the market over the period 2022-2027.
- Heightened research activities of market players in their quest of fabricated a more effective drug are said to be a preeminent driver driving the growth of the Anaplastic Astrocytoma Market. Lower chances of survival and high cost of cures are said to reduce the market growth.
- Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Anaplastic Astrocytoma Market report.
Anaplastic Astrocytoma Market Share, By Geography (%) in 2021
For More Details on This Report - Request for Sample
Anaplastic Astrocytoma Market Segment Analysis-By Treatment Type
The Anaplastic Astrocytoma Market based on the treatment type can be further segmented into surgery, chemotherapy, and radiation. The surgery segment held the largest share in 2021. The surgery has acquired the first-line treatment of anaplastic astrocytoma. In the treatment of almost every diagnosed case patient is first administered surgery in order to remove the tumor. Chemotherapy and radiation surgery are used very rarely for higher stages that too if tumor cells are spreading with extreme speed. In several cases, surgery is performed in combination with other methods like radiotherapy. The reason behind using them in combination is the minimally invasive nature of radiotherapy. Gamma knife radiosurgery is usually considered to reduce the overall size of the tumor with minimum bleeding. Similarly, the same segment is estimated to be the fastest-growing segment with a CAGR of 5.4% over the forecast period 2022-2027. This growth is owing to high effectiveness and precision in killing the tumor cells.
Anaplastic Astrocytoma Market Segment Analysis-By Disease Grades
The Anaplastic Astrocytoma Market based on disease grades can be further segmented into a low grade (Grade1, Grade2), and high grade (Grade3, Grade4). The lower grade segment held the largest share in 2021. The growth is owing to more prevalence as compared to high-grade tumors. The effectiveness of available medical procedures in treating low-grade gliomas is a significant factor in helping this segment in maintaining the lead. Generally, all tumors develop as lower grade and are of non-malignant nature. But over time they start to become worse as most people are unaware of them and don’t undergo timely treatments. In adults aged between 18-40, the lower grade tumor is quite common. Furthermore, the low-grade segment is estimated to be the fastest-growing segment with a CAGR of 5.9% over the forecast period 2022-2027. This growth is owing to a lack of curing procedures for higher-grade brain tumors. Grade 3 and Grade 4 gliomas spread like wildfire and the chance of survival are minuscule even after undergoing full treatments. Consequently, after confronting the reality many people chose to spend their final moments with their loved ones, not on a hospital bed.
Anaplastic Astrocytoma Market Segment Analysis-By Geography
The Anaplastic Astrocytoma Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 40% of the overall market in 2021. The growth in this segment is owing to the factors such as the higher prevalence of anaplastic astrocytoma as compared to other parts of the world. Exposure to radiation is one of the biggest causes of this life-threatening condition and the US leads the entire world in terms of nuclear power plants. The US has 93 nuclear power plants as of 2021. On another hand, better healthcare infrastructure such as state-of-the-art hospitals, research labs, and availability of top-of-the-line medical professionals is another reason behind the domination of North America in respective fields. However, Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to heavy pressure on Asian nations such as India and China to cut their carbon emissions and shift to nuclear energy. As a result of which these nations are implanting more and more nuclear power plants which are putting the health of people residing around such facilities at risk. Moreover. With prospering economies, the healthcare infrastructure of Asian states is improving and treating millions of people every year.
Anaplastic Astrocytoma Market Drivers
Broadening number of nuclear power plants worldwide is Anticipated to Boost Product Demand
Even though countries around the globe give too much emphasis and talk about clean energy but still coal is the most prominent source of electricity production. India and China are the biggest users of coal. According to a report, India produces around 74-75% of the electricity which is over 100 billion units with the help of coal. Consequently, both nations faced widespread criticism for their carbon emissions at the COP-26 summit held in Glasgow last year. Therefore, every nation worldwide is trying to shift to nuclear energy to reduce environmental pollution and alter climate change. As of 2021, there were around 441 nuclear power plants in the world and the majority of them are in France, U.S., India, and China. This shift toward nuclear energy may be good for the environment’s health but not for human health as radiation exposure stimulates tumor prevalence.
Proliferating stress and depression cases are Expected to Boost Product Demand
The world we are residing in has changed completely over the years. Our way of living, earning, communicating, and working has witnessed sweeping changes. The ever-growing competition has made people give a little extra in their pursuit of living a healthy life and nowadays this “Extra” which is considered a success determining factor is emerging as the biggest reason behind stress and depression cases. On another hand, yearlong lockdowns have dragged people into depression. Around 8 in 10 adults have stress issues due to pandemics. According to the American Institute of Stress published in 2021 around 31-33% of people went through extreme stress and out of this 33% more than half that is around 75-77% develop health issues. Therefore, such proliferation in stress cases is expected to arise as a driving factor in the growth of the anaplastic astrocytoma market.
Anaplastic Astrocytoma Market Challenges
Lower survival rates and high cost of treatments are Anticipated to Hamper Market Growth
Considering the rare nature of astrocytoma brain tumor there is no sure-fire way that is 100% effective in treating this condition. The higher-grade tumor (Grade 3, Grade 4) is of a highly malignant nature and spread very quickly. Moreover, there are no treatments to cure and restrain its spread which means 85-90% of cases patients lose their lives. This factor may turn many afflicted people half-heartedly into undergoing surgeries and waste thousands of dollars. Besides tumor surgeries are too risky and expensive. On average brain tumor surgery can up to $50,000 to $140,000.
Anaplastic Astrocytoma Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anaplastic Astrocytoma Market. Key companies of this market are:
- Pfizer Inc.
- Amgen Inc.
- Novartis International AG
- F. Hoffmann-La Roche AG
- Axelar Inc.
- Isarna Therapeutics GmbH
- Mylan N.V.
- Teva Pharmaceutical industries
- Merck & Co.
- Genetech Inc.
- On November 22, 2021, New Jersey, United States-based pharmaceutical company “Merck” announced its successful acquisition of a clinical-stage biopharma firm “Acceleron Pharma.” The acquisition was brought to a close with an $11.5billion payment to Acceleron. In addition to that, the transaction is believed to extend Merck several advantages in order to expand its cardiovascular illnesses portfolio.
- On April 16, 2021, California, United states-based biopharmaceutical company “Amgen” announced that it has acquired “Five Prime Therapeutics.” Five Prime is famous for its antibody therapeutics and proteins. The total value of this transaction stands at around $1.9 billion. The existing shareholder of five prime received around $38 per share in cash.
- On November 6, 2020, Swiss pharmaceutical player “Novartis” acquired New-jersey, United-based “The medicine Company.” A total amount of $9.7 billion with $85 per share was paid by Novartis in order to wrap up the acquisition process. According to experts the only intention of Novartis behind this acquisition was to acquire a drug “Inclisiran” developed by the Medicine company.
Brain Monitoring Market – Forecast (2022 - 2027)
Report Code: HCR 0089
Brain Implants Market – Forecast (2022 - 2027)
Report Code: HCR 0163
Brain Tumor Treatment Market - Forecast(2022 - 2027)
Report Code: HCR 0257
For more Lifesciences and Healthcare Market reports, please click here